论文部分内容阅读
目的探讨瑞舒伐他汀钙对急性冠状动脉综合征(ACS)患者介入术后发生造影剂肾病(CIN)的影响。方法选取2012年9月至2014年9月山东淄博市第四人民医院收治的拟行介入治疗的128例ACS患者作为研究对象,按随机数字表法将其分为对照组与观察组,各64例。两组患者均行经桡动脉介入治疗,对照组患者术前术后均行水化疗法,观察组患者在对照组基础上术后服用瑞舒伐他汀钙,比较两组患者的CIN发生率、治疗前后肾功能及不良反应发生情况。结果观察组患者CIN发生率为1.6%(1/64),明显低于对照组的14.1%(9/64),差异有统计学意义(P<0.05);治疗后72 h,两组患者的血肌酐、血尿素氮及尿β2微球蛋白水平均明显高于治疗前,但观察组患者的血尿素氮及尿β2微球蛋白水平均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者的不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀钙能有效预防ACS介入治疗术后CIN的发生,保护患者肾功能,减少不良反应发生。
Objective To investigate the effect of rosuvastatin calcium on contrast-induced nephropathy (CIN) after interventional therapy in patients with acute coronary syndrome (ACS). Methods From September 2012 to September 2014, Zibo City, Shandong Province People’s Hospital of the Fourth People’s Hospital to be planned interventional treatment of 128 patients with ACS as the research object, according to the random number table method is divided into control group and observation group, each 64 example. Both groups underwent radial artery intervention. Patients in the control group received preoperative and postoperative hydration. Patients in the observation group received rosuvastatin calcium after the operation on the basis of the control group. The incidence of CIN was compared between the two groups Before and after renal function and adverse reactions occurred. Results The incidence of CIN in observation group was 1.6% (1/64), which was significantly lower than that in control group (14.1%, 9/64) (P <0.05). At 72 hours after treatment, the incidence of CIN Serum creatinine, blood urea nitrogen and urine β2 microglobulin levels were significantly higher than before treatment, but the observation group of patients with blood urea nitrogen and urinary β2 microglobulin levels were significantly lower than the control group, the differences were statistically significant (both P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion Rosuvastatin calcium can effectively prevent the occurrence of CIN after ACS intervention, protect renal function and reduce adverse reactions.